Pharma/Biotech IP Due Diligence

Venue: TBC

Location: Amsterdam, Netherlands

Event Date/Time: Oct 28, 2008 End Date/Time: Oct 29, 2008
Registration Date: Oct 21, 2008
Report as Spam


As M&A, licensing and collaborative activity continues to shatter records, the due diligence process has assumed greater significance in Pharma/Biotech deals. Although it appears awkward, expensive and burdensome, due diligence is a necessary pre-requisite and is often the gating event in transactions.

According to one source, as much as ¾ of the value of publicly traded companies in the US come from intangible assets. Therefore if intellectual property due diligence is not properly conducted, companies face the risk of loss of reputation, loss of profits, or even ruin.
This conference will provide you with the latest updates on patent practice and reform, conducting a diligence review and highlight the best practices you need to ensure your due diligence strategies are equipped set up to make the most of potential Pharma/Bio transactions.
Don't miss the opportunity to hear from industry leading experts and their advisors.